OLEMA PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $2.21 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-03-16
- OLEMA PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $2.21M, a 56.63% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $1.41M, a 126.12% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $624.00K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2024-12-31 | $2.21M 10-K · filed 2026-03-16 |
| 2023-12-31 | $1.41M 10-K · filed 2025-03-18 |
| 2022-12-31 | $624.00K 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |